Skip to main content
U.S. flag

An official website of the United States government

Milestone 2.H

Continue to support cross-disciplinary research to discover and understand disease mechanisms that are common between AD and other neurodegenerative disorders including rare disorders and leverage these for therapy development. These efforts should include discovering new pathways leading to synaptic and neural damage understanding the structural variations of pathogenic peptides collected from well-phenotyped, diverse cohorts to inform the design of structure-specific imaging agents and inhibitors with therapeutic potential.


Success Criteria

  • Identify and preclinically validate at least three novel therapeutic targets that are common to AD and at least two other neurodegenerative disorders. 
  • Launch a minimum of three drug discovery projects targeting pathways common across AD at least two other neurodegenerative disorders.

Summary of Key Accomplishments

NIA supports research aimed at understanding disease mechanisms that are common between AD and other neurodegenerative disorders. This is achieved through one targeted funding initiative, other broad funding initiatives, and via investigator-initiated research. Six projects have been supported through the targeted funding initiative Common Mechanisms and Interactions Among Neurodegenerative Diseases. Collectively, these projects investigate the shared mechanisms among AD, Parkinson’s, Lewy body dementia and Huntington’s disease. The insights from this program have the potential to identify novel shared targets for multiple disorders.

This information is current as of March 2022.


Research Implementation Area
Research on Disease Mechanisms
Timeline
2018–2024
Status
In Progress

Accomplishments/Implementation Activities

Funding Initiatives

Research Programs and Resources

Research Highlights

Relevant Recommendations